Health Canada Approves Merck’s Keytruda As A Monotherapy To Treat MSI-H Or DMMR Solid Tumours
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Merck & Co Inc. (MRK) on Thursday said that Health Canada has granted approval of Keytruda as a monotherapy to treat patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1064987572-1a79077cb179458dbbcecc5ac1b660df.jpg "Average Equity In U.S. Homes: Overview, FAQs")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-769720227_2400a-31d6e8ea286f4dea9c854eaf18af463c.jpg "Planning for Retirement? Start With These 5 Steps")
:max_bytes(150000):strip_icc():format(jpeg)/Primary-Image-how-to-trade-0dte-options-7481013-c9af6887219942dc9c8c9374963b51ec.jpg "How to Trade 0DTE Options")
